Navigation Links
Cyberonics Reports Strong Fiscal 2010 First Quarter Results

HOUSTON, Aug. 19 /PRNewswire-FirstCall/ -- Cyberonics, Inc. (Nasdaq: CYBX) today announced results for the quarter ended July 24, 2009.

Quarterly highlights

Results for the first quarter of fiscal 2010 compared to the first quarter of fiscal 2009 include:

  • Net sales of $38.5 million, a 14% increase from $33.7 million;
  • Income from operations of $6.5 million, an increase of 134% from the $2.8 million reported in the prior year;
  • Earnings per diluted share of $0.23 cents compared with $0.08 cents per share;
  • U.S. and international epilepsy unit sales increased by 8%, and 15%, respectively.

Net sales

Worldwide net sales for the first quarter of fiscal 2010 were $38.5 million compared to $33.7 million in the comparable period of fiscal 2009, an increase of 14%. On a constant currency basis, the year-over-year sales increase was approximately 17%.

U.S. net product sales increased to $30.9 million, compared with $26.2 million in the comparable period of fiscal 2009, an increase of $4.7 million or 18%.

While overall international unit sales increased by 12% in the first quarter of fiscal 2010, net sales increased by only 1% to $7.2 million due to the negative impact of foreign currency movements. On a constant currency basis, international net sales increased by approximately 14%.

Gross profit

The gross profit for the first quarter of fiscal 2010 represented 86.1% of net sales, slightly higher than the 85.7% in the first quarter of fiscal 2009. This increase is primarily a result of higher prices, increased production volumes and improved manufacturing e ---------- ---------- Net Cash Provided By Operating Activities 4,011,161 6,609,670 Cash Flow From Investing Activities: Net Cash Used in Investing Activities (715,340) (216,533) Cash Flow From Financing Activities: Repurchase of convertible notes (13,845,400) - Proceeds from issuance of Common stock 389,626 4,057,306 Purchase of treasury stock (37,551) (105,110) ------- -------- Net Cash Provided By (Used in) Financing Activities (13,493,325) 3,952,196 ----------- --------- Effect of Exchange Rate Changes on Cash and Cash Equivalents 230,236 (255,209) ------- -------- Net Increase (Decrease) in Cash and Cash Equivalents (9,967,268) 10,090,124 Cash and Cash Equivalents at Beginning of Period 66,225,479 91,058,692 ---------- ---------- Cash and Cash Equivalents at End of Period $56,258,211 $101,148,816 =========== ============


Operating expenses

Operating expenses increased by $0.5 million to $26.6 million for the first quarter of fiscal 2010 from the $26.1 million recorded in the comparable period of fiscal 2009 and were materially unchanged from the $26.8 million in the fourth quarter of the recently completed fiscal year.

Expenses for the quarter ended July 24, 2009 included $2.2 million for stock-based compensation, a reduction of $0.4 million from the comparable period of fiscal 2009.

Income from operations

The company reported income from operations of $6.5 million during the first quarter of fiscal 2010, compared with income from operations of $2.8 million in the comparable period of fiscal 2009.

Debt repurchase / other income

During the recently completed quarter, the company repurchased $15.6 million of its outstanding convertible debt for total cash consideration of $13.8 million and recorded a net gain of approximately $1.5 million, including the impact of tax and the accelerated amortization of deferred issuance costs. Since January 2008, the company has retired a total of $85.8 million of debt, including $78.3 million of convertible debt. Convertible debt outstanding as of the date of this release totals $46.7 million.

Net income

The company reported net income of $7.9 million, or $0.23 per diluted share, for the first quarter, compared with a net income of $2.1 million, or $0.08 cents per share, in the first quarter of fiscal 2009.

Balance sheet and cash flow

The company reported operating cash flow of $4.0 million for the quarter ended July 24, 2009. Available cash balances were $56.3 million at quarter end, compared with debt outstanding of $46.7 million.

Results and objectives

"Consistent with our expectations, fiscal 2010 has begun on a positive note, with a double-digit sales increase," commented Dan Moore, Cyberonics' President and Chief Executive Officer. "Again, we achieved strong growth in operating and net income. Our core U.S. epilepsy business showed continued growth, and our international operations posted another solid performance, with international units increasing almost 12% and revenues again exceeding $7 million.

"During the quarter, we made significant progress in obtaining physician input to our development programs, reinforcing Cyberonics as the leader in devices for epilepsy, and rebuilding our credibility. We conducted six meetings with a total of 71 epilepsy physicians during which we provided considerable detail on the enhanced development efforts around seizure detection, seizure recording and responsive stimulation. Two additional educational symposia with epilepsy specialists were held during the quarter, and more than 20 are planned for the fiscal year. Feedback from these and other physician meetings provide important input into our product development process.

"With respect to our international business, unit growth has continued to improve this quarter. We sold the VNS Therapy(TM) System into 41 countries during the quarter, indicative of its widespread acceptance as an important treatment option. We are also pleased to report that the Japanese regulatory authorities have scheduled the audit of our quality system for the first week of September. This represents another important milestone in making VNS Therapy available to Japanese patients with epilepsy.

"With our recent filing of our 2009 proxy statement, we announced that two of our long-standing directors would not be standing for reelection and that the Board would be reduced to seven from the date of our shareholder meeting on September 24. Both Alan Olsen and Michael Strauss have made important and valuable contributions to the company, and we thank them for all of their efforts."

Fiscal 2010 guidance

Cyberonics is reiterating its previously provided net sales guidance of $157 million to $161 million on a constant currency basis, and continues to expect that income from operations will be in the range of $24 million to $27 million.

Additional details will be provided during the upcoming conference call and in the accompanying presentation slides, as described below.

Fiscal Year 2010 First Quarter Results Conference Call Instructions

A conference call to discuss fiscal 2010 first quarter results will be held at 9:00 AM EDT on Thursday, August 20, 2009. To listen to the conference call live by telephone dial 877-313-8035 (if dialing from within the U.S.) or 706-679-4838 (if dialing from outside the U.S.). The conference ID is 21678611; the leader is Dan Moore. Presentation slides will be available on-line at by 8:00 AM EDT on Thursday, August 20, 2009. A replay of the conference call will be available approximately two hours after the completion of the live call by dialing 800-642-1687 (if dialing from within the U.S.) or 706-645-9291 (if dialing outside the U.S.). The replay conference ID access code is 21678611.

The replay will be available for one week on the above number, and subsequently on the Company's website for a period of six months.

About VNS Therapy(TM) and Cyberonics

Cyberonics, Inc. (NASDAQ: CYBX) is a medical technology company with core expertise in neuromodulation. The company developed and markets the Vagus Nerve Stimulation (VNS) Therapy(TM) System, which is FDA-approved for the treatments of epilepsy and depression. The VNS Therapy System uses a surgically implanted medical device that delivers electrical pulsed signals to the vagus nerve. Cyberonics markets the VNS Therapy System in selected markets worldwide.

Additional information on Cyberonics, Inc. and VNS Therapy(TM) is available at and

Safe harbor statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology, including "may," "believe," "will," "expect," "anticipate," "estimate," "plan," "intend," "forecast," or other similar words. Statements contained in this press release are based on information presently available to us and assumptions that we believe to be reasonable. We are not assuming any duty to update this information if those facts change or if we no longer believe the assumptions to be reasonable. Investors are cautioned that all such statements involve risks and uncertainties, including without limitation, statements concerning obtaining regulatory approval in Japan for the epilepsy indication, maintaining leadership in the epilepsy device market, successfully developing a product capable of seizure detection, seizure recording and responsive stimulation, fiscal 2010 sales of $157 million to $161 million, and fiscal 2010 operating income of $24 million to $27 million. Our actual results may differ materially. Important factors that may cause actual results to differ include, but are not limited to: continued market acceptance of VNS Therapy(TM) and sales of our product; the development and satisfactory completion of clinical trials and/or market test and/or regulatory approval of VNS Therapy(TM) for the treatment of other indications; satisfactory completion of post-market studies required by the U.S. Food and Drug Administration as a condition of approval for the treatment-resistant depression indication; adverse changes in coverage or reimbursement amounts by third-parties; intellectual property protection and potential infringement claims; maintaining compliance with government regulations and obtaining necessary government approvals for new indications; product liability claims and potential litigation; reliance on single suppliers and manufacturers for certain components; the accuracy of management's estimates of future expenses and sales; the results of the previously disclosed governmental inquiries; the potential identification of material weaknesses in our internal controls over financial reporting; risks and costs associated with such governmental inquiries and any litigation relating thereto or to our stock option grants, procedures, and practices and other risks detailed from time to time in our filings with the Securities and Exchange Commission (SEC). For a detailed discussion of these and other cautionary statements, please refer to our most recent filings with the SEC, including our Annual Report on Form 10-K for the fiscal year ended April 24, 2009.

    Contact information

    Greg Browne, CFO
    Cyberonics, Inc.
    100 Cyberonics Blvd.
    Houston, TX 77058
    Main: (281) 228-7262
    Fax: (281) 218-9332

                            CYBERONICS, INC. AND SUBSIDIARY

                                                        For the
                                                  Thirteen Weeks Ended
                                               July 24,           July 25,
                                                 2009               2008
                                                 ----               ----

    Net sales                                $38,501,237        $33,731,858
    Cost of sales                              5,340,145          4,816,762
                                               ---------          ---------
        Gross Profit                          33,161,092         28,915,096
                                              ----------         ----------
    Operating Expenses:
      Selling, general and administrative     21,618,891         21,524,767
      Research and development                 5,030,089          4,608,175

                                              ----------         ----------
        Total Operating Expenses              26,648,980         26,132,942
                                              ----------         ----------
        Income from Operations                 6,512,112          2,782,154
    Interest income                               42,263            508,287
    Interest expense                            (502,685)        (1,161,650)
                                                --------         ----------
    Gain on early extinguishment of debt, net  1,524,330                  -
    Other income, net                            492,889             17,234
                                                 -------             ------
    Income before income tax                   8,068,909          2,146,025
    Income tax expense                           203,450             93,224

      Net income                              $7,865,459         $2,052,801
                                              ==========         ==========

    Basic income per share                         $0.29              $0.08
    Diluted income per share                       $0.23              $0.08
                                                   -----              -----

    Shares used in computing basic income
     per share                                27,532,410         26,420,783
    Shares used in computing Diluted
     income per share                         27,748,461         26,799,038
                                              ==========         ==========

                            CYBERONICS, INC. AND SUBSIDIARY

                           (Unaudited except where indicated)

                                                July 24,         April 24,
                                                  2009             2009
                                                --------         ---------

    Current Assets
      Cash and cash equivalents                $56,258,211      $66,225,479
      Restricted cash                            1,000,000        1,000,000
      Accounts receivable, net                  24,963,824       22,250,653
      Inventories                               13,548,831       12,841,064
      Other current assets                       2,419,672        2,216,706
                                                 ---------        ---------
          Total Current Assets                  98,190,538      104,533,902
    Property and equipment, net and other
     assets                                      7,438,309        7,509,726
                                                 ---------        ---------
    Total Assets                              $105,628,847     $112,043,628
                                              ============     ============


    Current Liabilities                        $16,753,850      $17,645,240
    Long Term Liabilities:
    Convertible notes                           46,715,000       62,339,000
    Deferred license revenue and other           7,272,821        7,647,544
                                                 ---------        ---------
    Total Long Term Liabilities                 53,987,821       69,986,544
    Total Liabilities                           70,741,671       87,631,784
    Total Stockholders' Equity                  34,887,176       24,411,844
                                                ----------       ----------
    Total Liabilities and Stockholders'
     Equity                                   $105,628,847     $112,043,628
                                              ============     ============

                           CYBERONICS, INC. AND SUBSIDIARY

                                                    Thirteen Weeks Ended
                                                  July 24,         July 25,
                                                    2009             2008
                                                    ----             ----
    Cash Flow From Operating Activities:
    Net Income                                  $7,865,459        $2,052,801
      Non-Cash items included in Net Income
        Gain on early extinguishment of debt    (1,524,330)                -
        Stock-base compensation                  2,203,438         2,626,762
        Unrealized (gain) loss in Foreign
         currency transactions                    (591,026)          189,404
        Other                                      201,855           478,164
    Changes in Operating Assets and Liabilities
        Accounts receivable, net                (2,284,773)        1,864,232
        Inventories                               (588,709)          431,849
        Other                                   (1,270,753)       (1,033,542)
SOURCE Cyberonics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cyberonics to Present at Canaccord Adams 29th Annual Global Growth Conference
2. Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 First Quarter Financial Results
3. Cyberonics Announces Exclusive Distribution Agreement With Nihon Kohden in Japan
4. Cyberonics Names Bryan D. Olin, Ph.D. Vice President, Quality
5. Cyberonics Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2009 Financial Results
6. Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter
7. Cyberonics Announces Conference Call to Discuss Fiscal Year 2009 Third Quarter Financial Results
8. Cyberonics Names Milton M. Morris, Ph.D. Vice President, Research & Development
9. Cyberonics to Present at Piper Jaffray 20th Annual Health Care Conference
10. Cyberonics Reports Strong Sales Growth and Profitability in Fiscal 2009 Second Quarter
11. Cyberonics Announces Conference Call to Discuss Fiscal Year 2009 Second Quarter Financial Results
Post Your Comments:
(Date:10/10/2015)... ... October 10, 2015 , ... Well-known Eastern ... to be recognized by The National Law Journal for inclusion in their second ... firms across the United States who obtained the largest awards for their personal ...
(Date:10/9/2015)... California (PRWEB) , ... October 09, 2015 , ... ... Osteopathic Medicine of the Pacific Associate Dean for Graduate Medical Education J. Michael ... of the Year Award. Finley was selected for his impact on graduate medical ...
(Date:10/9/2015)... ... October 09, 2015 , ... With the FCPX LUT Vibrance pack from ... A LUT is a Lookup Table that contains a mathematical formula for modifying an ... table. This pack comes with 60 vibrant CUBE LUT files. , Inspired ...
(Date:10/9/2015)... ... October 09, 2015 , ... Smoke alarms can save lives. In fact, ... risk of dying in reported home fires in half. As part of Fire Prevention ... are property installed and maintained. , Half of home fire deaths result from fires ...
(Date:10/9/2015)... ... , ... Head Over Heels Athletic Arts gymnast, Madelyn Williams, will attend the ... in Huntsville, Texas on October 17-21. , "It's very exciting to be invited ... executive director, said. “It's a stepping stone into the U.S. elite system where Maddie ...
Breaking Medicine News(10 mins):
... Neuroscientists at MIT,s Picower Institute of Learning and Memory have ... inexplicably linked to long-term memories. The work is slated to ... "Our finding explains, at least partially, why seemingly irrelevant ... person is remembered as vividly as more significant information such ...
... HealthDay Reporter , THURSDAY, Jan. 13 (HealthDay News) -- This winter ... instead is turning out to be a more typical flu season, ... to get a flu shot, advice that seniors in particular should ... their age group the hardest, the experts added. The H1N1 flu ...
... for Injury Biomechanics ( ) has been awarded ... Research and Materiel Command for phase 2 of an ... military personnel. Specifically, blast induced brain trauma will be ... helmet design and body armor and the resulting reductions ...
... Liverpool-led consortium has received $1.5million from the Bill & ... serious disease and epidemics in sub-Saharan Africa. Streptococcus ... in sub-Sahara Africa. The funding will enable scientists ... associated with invasive pneumococcal disease, why it spreads so ...
... HealthDay Reporter , THURSDAY, Jan. 13 (HealthDay ... by patients and health professionals alike to save money ... and potentially dangerous, a new study suggests. Belgian ... deviated from recommended dosages by 15 percent or more. ...
... HealthDay Reporter , WEDNESDAY, Jan. 12 (HealthDay News) -- ... said Tuesday, breathing on her own and moving both arms ... "She has a 101 percent chance of surviving," Dr. ... told the Associated Press . "She will not die." ...
Cached Medicine News:
(Date:10/8/2015)... Oct. 9, 2015 Johnson & Johnson (NYSE: ... immunogenicity clinical trial in Sierra Leone ... Janssen Pharmaceutical Companies. Trial recruitment is underway, and the first ... first study conducted of Janssen,s Ebola prime-boost vaccine regimen in ... Sierra Leone,s Kambia district, where ...
(Date:10/8/2015)...  Ardelyx, Inc. (NASDAQ: ARDX ), a ... diseases, today announced that clinical data for the ... at the 2015 American College of Gastroenterology (ACG) ... sustained response in IBS-C patients enrolled in the ... trial. The meeting will be held in ...
(Date:10/8/2015)... SAN DIEGO , Oct. 8, 2015 /PRNewswire/ ... cell-free molecular diagnostics, today announced the presentation of ... use of its Precision Cancer Monitoring SM ... can be critical for physicians to determine appropriate ... chief scientific officer of Trovagene is delivering the ...
Breaking Medicine Technology:
... February is American Heart Month and a time when ... on their family history of heart disease and recommit ... teaming up with the makers of Bayer® Aspirin and ... to raise $100,000 for the fight against heart disease. ...
... 2012 Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL ... the Leerink Swann 2012 Global Healthcare Conference to be ... New York City.  Mr. Adrian Adams, Chief Executive Officer ... the Company and its product pipeline at 10:30 a.m. ...
Cached Medicine Technology:
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: